Pathophysiology of Na and water retention in liver cirrhosis and its correction with vasoconstrictors and aquaretics

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.16, Iss.1, 2006-01, pp. : 59-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness of Recombinant Human Serum Albumin in the Treatment of Ascites in Liver Cirrhosis - a proposal for the initiation of renal sodium and water retention in cirrhosis

By Horie S. Nagai H. Yuuki T. Hanada S. Nakamura N.

General Pharmacology, Vol. 31, Iss. 5, 1998-11 ,pp. : 811-815

Elsevier

Access to resources Recommend Favorite

Aquaretics

By Thibonnier M.

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 223-235

Informa Healthcare

Access to resources Recommend Favorite

The bradykinin B 2 receptor antagonist Icatibant (HOE 140) corrects avid Na + retention in rats with CCl 4 -induced liver cirrhosis: possible role of enhanced microvascular leakage

By Wirth K.J. Bickel M. Hropot M. Gunzler V. Heitsch H. Ruppert D. Scholkens B.A.

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 45-53

Elsevier

Access to resources Recommend Favorite

Role of Bactericidal/Permeability-Increasing Protein (BPI) in Sepsis and Liver Cirrhosis, and Its Clinical Implications

Anti-Infective Agents, Vol. 14, Iss. 2, 2016-09 ,pp. : 76-83

Bentham Science Publishers

Access to resources Recommend Favorite

Screening for liver cancer worth it in cirrhosis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 407, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite